We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 03, 2020

PI3K Mutations Detected in Liquid Biopsy Are Associated With Reduced Sensitivity to CDK4/6 Inhibitors in Metastatic Breast Cancer Patients

Pharmacological Research

 

Additional Info

Pharmacological Research
PI3K Mutations Detected in Liquid Biopsy Are Associated to Reduced Sensitivity to CDK4/6 Inhibitors in Metastatic Breast Cancer Patients
Pharmacol Res 2020 Oct 10;[EPub Ahead of Print], M Del Re, S Crucitta, G Lorenzini, C De Angelis, L Diodati, D Cavallero, I Bargagna, P Cinacchi, B Fratini, B Salvadori, M Ghilli, M Roncella, A Fontana, R Danesi, F Cucchiara

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading